{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:22:41Z","timestamp":1775182961122,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.msard.2022.103735","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:52:59Z","timestamp":1646999579000},"page":"103735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-8192","authenticated-orcid":false,"given":"Tyler E","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gratch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneek","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Sammarco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Rimler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Zuniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dunia","family":"Gragui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Charvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana Zhovtis","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.msard.2022.103735_bib0001","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1016\/j.vaccine.2021.08.078","article-title":"Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies","volume":"39","author":"Ali","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2022.103735_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM","author":"Alonso","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1016\/j.msard.2022.103735_bib0003","first-page":"e1024","article-title":"SARS-CoV-2 Infection in Multiple Sclerosis","volume":"8","author":"Arrambide","year":"2021","journal-title":"Results of the Spanish Neurology Society Registry"},{"issue":"5","key":"10.1016\/j.msard.2022.103735_bib0004","first-page":"e1055","article-title":"Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti\u2013SARS-CoV-2 Antibodies","volume":"8","author":"Bigaut","year":"2021","journal-title":"An Observational Study"},{"issue":"7","key":"10.1016\/j.msard.2022.103735_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255316","article-title":"COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry","volume":"16","author":"Bsteh","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.103735_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/13524585211049391","article-title":"\"Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study","author":"Bsteh","year":"2021","journal-title":"Mult Scler:"},{"key":"10.1016\/j.msard.2022.103735_bib0007","article-title":"National Notifiable Diseases Surveillance System (NNDSS) Coronavirus Disease 2019 (COVID-19)","year":"2019","journal-title":"Coronavirus Disease"},{"key":"10.1016\/j.msard.2022.103735_bib0009","unstructured":"Centers for Disease Control and Prevention (2021). \u201cScience Brief: Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19\u201d."},{"key":"10.1016\/j.msard.2022.103735_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117147","article-title":"COVID-19 in multiple sclerosis patients and risk factors for severe infection","volume":"418","author":"Chaudhry","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.msard.2022.103735_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis","author":"Disanto","year":"2021","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.103735_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2022.103735_bib0013","article-title":"Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis","author":"Etemadifar","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.msard.2022.103735_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103173","article-title":"Coronavirus disease 2019 in Latin American patients with multiple sclerosis","volume":"55","author":"Fragoso","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103735_bib0015","doi-asserted-by":"crossref","unstructured":"Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020;55(5):2000547. doi:10.1183\/13993003.00547-2020.","DOI":"10.1183\/13993003.01227-2020"},{"key":"10.1016\/j.msard.2022.103735_bib0016","article-title":"COVID-19 in ocrelizumab-treated people with multiple sclerosis","volume":"49","author":"Hughes","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.msard.2022.103735_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250319","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and \u201cReopening","volume":"16","author":"Jin","year":"2021","journal-title":"PLOS ONE"},{"issue":"9","key":"10.1016\/j.msard.2022.103735_bib0018","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 \u2014 looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nature Reviews Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103735_bib0019","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"10.1016\/j.msard.2022.103735_bib0020","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/1352458520942198","article-title":"COVID-19 in multiple sclerosis: The Dutch experience","volume":"26","author":"Loonstra","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1016\/j.msard.2022.103735_bib0021","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.msard.2022.103735_bib0022","article-title":"Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders","author":"Louapre","year":"2021","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry: jnnp-2021-326904"},{"issue":"11","key":"10.1016\/j.msard.2022.103735_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34147","article-title":"Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Meta-analysis","volume":"4","author":"Magesh","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.msard.2022.103735_bib0024","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00415-020-10015-1","article-title":"COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis","volume":"268","author":"Mantero","year":"2021","journal-title":"J Neurol"},{"issue":"15","key":"10.1016\/j.msard.2022.103735_bib0025","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.103735_bib0026","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s10072-021-05373-1","article-title":"The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"42","author":"Moghadasi","year":"2021","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1016\/j.msard.2022.103735_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124067","article-title":"Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases","volume":"9","author":"M\u00f6hn","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.msard.2022.103735_bib0028","article-title":"COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: what we know by May 2021","author":"Naghavi","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"10.1016\/j.msard.2022.103735_bib0029","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12889-021-10207-y","article-title":"Socioeconomic disparity and the risk of contracting COVID-19 in South Korea: an NHIS-COVID-19 database cohort study","volume":"21","author":"Oh","year":"2021","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.msard.2022.103735_bib0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2022.103735_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103217","article-title":"COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study","volume":"55","author":"P\u00e9rez","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.103735_bib0032","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103735_bib0033","article-title":"Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies","author":"Prosperini","year":"2021","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1016\/j.msard.2022.103735_bib0034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","article-title":"COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies","volume":"35","author":"Reder","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2022.103735_bib0035","article-title":"COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register","author":"Rm","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.msard.2022.103735_bib0036","doi-asserted-by":"crossref","unstructured":"Sabatino, J. J., K. Mittl, W. Rowles, K. McPolin, J. V. Rajan, C. R. Zamecnik, R. Dandekar, B. D. Alvarenga, R. P. Loudermilk, C. Gerungan, C. M. Spencer, S. A. Sagan, D. G. Augusto, J. Alexander, J. A. Hollenbach, M. R. Wilson, S. S. Zamvil and R. Bove (2021). \u201cImpact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.\u201d medRxiv.","DOI":"10.1101\/2021.09.10.21262933"},{"key":"10.1016\/j.msard.2022.103735_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103735_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.msard.2022.103735_bib0039","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis","volume":"78","author":"Salter","year":"2021","journal-title":"JAMA Neurology"},{"issue":"7880","key":"10.1016\/j.msard.2022.103735_bib0040","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-021-03914-4","article-title":"Burden and characteristics of COVID-19 in the United States during 2020","volume":"598","author":"Sen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.msard.2022.103735_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102968","article-title":"The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?","volume":"52","author":"Sen","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"10.1016\/j.msard.2022.103735_bib0042","first-page":"e954","article-title":"Incidence and Impact of COVID-19 in MS","volume":"8","author":"Sep\u00falveda","year":"2021","journal-title":"A Survey From a Barcelona MS Unit"},{"key":"10.1016\/j.msard.2022.103735_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102800","article-title":"COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review","volume":"50","author":"Sharifian-Dorche","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"19","key":"10.1016\/j.msard.2022.103735_bib0045","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis","volume":"97","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"issue":"0","key":"10.1016\/j.msard.2022.103735_bib0146","article-title":"SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study","volume":"0","author":"Sormani","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1016\/j.msard.2022.103735_bib0046","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.msard.2022.103735_bib0047","first-page":"e1105","article-title":"COVID-19 Severity in Multiple Sclerosis","volume":"9","author":"Sormani","year":"2022","journal-title":"Putting Data Into Context"},{"issue":"0","key":"10.1016\/j.msard.2022.103735_bib0049","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry","volume":"0","author":"Spelman","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"5","key":"10.1016\/j.msard.2022.103735_bib0050","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"Journal of Neurology"},{"issue":"46","key":"10.1016\/j.msard.2022.103735_bib0051","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.15585\/mmwr.mm6946a2","article-title":"COVID-19 Outbreak - New York City, February 29-June 1, 2020","volume":"69","author":"Thompson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.msard.2022.103735_bib0052","unstructured":"US Food & Drug Administration (FDA). (November 23, 2021). \"Comirnaty and Pfizer-BioNTech COVID-19 Vaccine.\" Retrieved November 23, 2021, from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/comirnaty-and-pfizer-biontech-covid-19-vaccine."},{"key":"10.1016\/j.msard.2022.103735_bib0053","unstructured":"US Food & Drug Administration (FDA). (November 23, 2021). \"Janssen COVID-19 Vaccine.\" Retrieved November 23, 2021, from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine."},{"key":"10.1016\/j.msard.2022.103735_bib0054","unstructured":"US Food & Drug Administration (FDA). (November 19, 2021). \"Moderna COVID-19 Vaccine.\" November 23, 2021, from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccine."},{"issue":"7","key":"10.1016\/j.msard.2022.103735_bib0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamaneurol.2021.1364","article-title":"SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort","volume":"78","author":"van Kempen","year":"2021","journal-title":"JAMA Neurology"},{"issue":"15 Supplement","key":"10.1016\/j.msard.2022.103735_bib0056","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1212\/WNL.94.15_supplement.5218","article-title":"Evaluation of Risk Factors in Developing Lymphopenia and Hypogammaglobulinemia in Anti-CD20 Treated Multiple Sclerosis Patients (5218)","volume":"94","author":"Vollmer","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103735_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102793","article-title":"The presence of SARS-CoV2 antibodies in MS patients","volume":"50","author":"Wallach","year":"2021","journal-title":"Mult Scler Relat Disord"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:00:50Z","timestamp":1761901250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822002504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":55,"alternative-id":["S2211034822002504"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103735","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103735"}}